Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug3962 | prophylactic lactoferrin daily Wiki | 0.71 |
drug14 | 0.9% Saline Wiki | 0.50 |
drug3264 | TY027 Wiki | 0.41 |
Navigate: Correlations HPO
There are 2 clinical trials
The management of patients with SARS-CoV2 in respiratory distress can expose to corneal or retinal lesions induced by the stay in intensive care. Examination by ophthalmologists would make it possible to detect the most of the ophthalmologic problems known in intensive care and to provide an early, preventive or curative therapeutic response when possible, in order to avoid irreversible visual loss. The object of the research is to assess the presence and the importance of surface ophthalmologic lesions, the presence and the importance of retinal or optic nerve lesions, in order to improve the monitoring and primary prevention of this population
Description: Direct exam
Measure: Describe ophthalmologic damage to the cornea with direct exam at day 0 Time: Day 0Description: Direct exam
Measure: Describe ophthalmologic damage to the cornea with direct exam at day 7 Time: Day 7Description: Direct exam
Measure: Describe ophthalmologic damage to the cornea with direct exam at day 14 Time: Day 14Description: Direct exam
Measure: Describe ophthalmologic damage to the cornea with direct exam at discharge of hospital Time: Discharge of hospital, up to 3 monthsDescription: Slit lamp exam
Measure: Describe ophthalmologic damage to the cornea with slit lamp exam at day 0 Time: Day 0Description: Slit lamp exam
Measure: Describe ophthalmologic damage to the cornea with slit lamp exam at day 7 Time: Day 7Description: Slit lamp exam
Measure: Describe ophthalmologic damage to the cornea with slit lamp exam at day 14 Time: Day 14Description: Slit lamp exam
Measure: Describe ophthalmologic damage to the cornea with slit lamp exam at discharge of hospital Time: Discharge of hospital, up to 3 monthsDescription: Shirmer test
Measure: Describe tear film anomalies at day 0 Time: Day 0Description: Shirmer test
Measure: Describe tear film anomalies at day 7 Time: Day 7Description: Shirmer test
Measure: Describe tear film anomalies at day 14 Time: Day 14Description: Shirmer test
Measure: Describe tear film anomalies at discharge of hospital Time: Discharge of hospital, up to 3 monthsDescription: Retinophotography
Measure: Describe ophthalmologic damage to the retina at day 0 Time: Day 0Description: Retinophotography
Measure: Describe ophthalmologic damage to the retina at day 7 Time: Day 7Description: Retinophotography
Measure: Describe ophthalmologic damage to the retina at day 14 Time: Day 14Description: Retinophotography
Measure: Describe ophthalmologic damage to the retina at discharge of hospital Time: Discharge of hospital, up to 3 monthsDescription: Retinophotography
Measure: Describe ophthalmologic damage to the optic nerve at day 0 Time: Day 0Description: Retinophotography
Measure: Describe ophthalmologic damage to the optic nerve at day 7 Time: Day 7Description: Retinophotography
Measure: Describe ophthalmologic damage to the optic nerve at day 14 Time: Day 14Description: Retinophotography
Measure: Describe ophthalmologic damage to the optic nerve at discharge of hospital Time: Discharge of hospital, up to 3 monthsOphthalmologic damages secondary to COVID-19 coronavirus infection are little described. The ocular involvement is probably multiple, ranging from pathologies of the anterior segment such as conjunctivitis and anterior uveitis to disorders that threaten vision such as retinitis or optic neuropathy. On the other hand, in addition to this impairment, when patients are hospitalized for acute respiratory failure, complications related to possible resuscitation, medication prescriptions, positioning and oxygenation. COVID-19 itself, has several components: - An apoptotic action of the viral attack which will generate cellular destruction, whether pulmonary, cardiac or renal or maybe ocular - A secondary autoimmune action with the development of major vascular inflammation, possibly reaching the retinal, choroidal, and optic nerve vessels. A secondary "hyper" inflammatory syndrome with flashing hypercytokinemia and multi-organ decompensation is described in 3,7% to 4 ,3% of severe cases. - A thromboembolic action
Description: Multimodal ophthalmologic imaging
Measure: Description of the ophthalmological problems observed Time: 6 months after discharge of hospitalizationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports